CARTITUDE-1 Study Demonstrates Promising Response Rates in Relapsed/Refractory Myeloma
Jesus G. Berdeja, MD, discusses the findings from the phase 2 results of ciltacabtagene autoleucel as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study.
Jesus G. Berdeja, MD, director of Myeloma Research at Sarah Cannon Research Institute, discusses the findings from the phase 2 results of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) as treatment of patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 study (NCT03548207).
Researchers were gratified by the results seen in this study, says Berdeja, especially in regard to the response rates. The objective response rate was 97% with 57% of patients achieving a stringent complete response and 92% a partial response or better.
According to Berdeja, the median progression-free survival had not been reached yet, but at 12-months, 76.6% of patients remained in remission in the study.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
